Joint Meeting of the Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee; Cancellation

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

March 2, 2023

Issuing agencies

Health and Human Services DepartmentFood and Drug Administration

Abstract

The meeting of the Nonprescription Drugs Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee scheduled for March 20, 2023, is cancelled. This meeting was announced in the Federal Register of January 30, 2023. The meeting is no longer needed.

Full Text

<html>
<head>
<title>Federal Register, Volume 88 Issue 41 (Thursday, March 2, 2023)</title>
</head>
<body><pre>[Federal Register Volume 88, Number 41 (Thursday, March 2, 2023)]
[Notices]
[Page 13130]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2023-04271]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2023-N-0094]


Joint Meeting of the Nonprescription Drugs Advisory Committee and 
the Anesthetic and Analgesic Drug Products Advisory Committee; 
Cancellation

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The meeting of the Nonprescription Drugs Advisory Committee 
and the Anesthetic and Analgesic Drug Products Advisory Committee 
scheduled for March 20, 2023, is cancelled. This meeting was announced 
in the Federal Register of January 30, 2023. The meeting is no longer 
needed.

FOR FURTHER INFORMATION CONTACT: Moon Choi, Center for Drug Evaluation 
and Research, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-2894, email: 
<a href="/cdn-cgi/l/email-protection#89c7cdc8cac9efede8a7e1e1faa7eee6ff"><span class="__cf_email__" data-cfemail="95dbd1d4d6d5f3f1f4bbfdfde6bbf2fae3">[email&#160;protected]</span></a>, or FDA Advisory Committee Information Line, 1-800-
741-8138 (301-443-0572 in the Washington, DC area), and follow the 
prompts to the desired center or product area. Please call the 
Information Line for up-to-date information on this meeting, which was 
announced in the Federal Register of January 30, 2023 (88 FR 5893).

    Dated: February 27, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-04271 Filed 3-1-23; 8:45 am]
BILLING CODE 4164-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on March 2, 2023.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.